Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

An economic framework to prioritize confirmatory tests after a high-throughput screen.

Swamidass SJ, Bittker JA, Bodycombe NE, Ryder SP, Clemons PA.

J Biomol Screen. 2010 Jul;15(6):680-6. doi: 10.1177/1087057110372803. Epub 2010 Jun 14.

2.

Enhancing the rate of scaffold discovery with diversity-oriented prioritization.

Swamidass SJ, Calhoun BT, Bittker JA, Bodycombe NE, Clemons PA.

Bioinformatics. 2011 Aug 15;27(16):2271-8. doi: 10.1093/bioinformatics/btr369. Epub 2011 Jun 17.

3.

Utility-aware screening with clique-oriented prioritization.

Swamidass SJ, Calhoun BT, Bittker JA, Bodycombe NE, Clemons PA.

J Chem Inf Model. 2012 Jan 23;52(1):29-37. doi: 10.1021/ci2003285. Epub 2011 Dec 20.

4.

Analysis of high-throughput screening assays using cluster enrichment.

Pu M, Hayashi T, Cottam H, Mulvaney J, Arkin M, Corr M, Carson D, Messer K.

Stat Med. 2012 Dec 30;31(30):4175-89. doi: 10.1002/sim.5455. Epub 2012 Jul 5.

5.

Enhanced HTS hit selection via a local hit rate analysis.

Posner BA, Xi H, Mills JE.

J Chem Inf Model. 2009 Oct;49(10):2202-10. doi: 10.1021/ci900113d.

PMID:
19795815
6.

False positives in the early stages of drug discovery.

Sink R, Gobec S, Pečar S, Zega A.

Curr Med Chem. 2010;17(34):4231-55. Review.

PMID:
20939815
7.

On the prediction of statistical parameters in high-throughput screening using resampling techniques.

Ilouga PE, Hesterkamp T.

J Biomol Screen. 2012 Jul;17(6):705-12. doi: 10.1177/1087057112441623. Epub 2012 Mar 29. Review. Erratum in: J Biomol Screen. 2012 Sep;17(8):1113.

PMID:
22460175
8.

Optimising experimental design for high-throughput phenotyping in mice: a case study.

Karp NA, Baker LA, Gerdin AK, Adams NC, Ramírez-Solis R, White JK.

Mamm Genome. 2010 Oct;21(9-10):467-76. doi: 10.1007/s00335-010-9279-1. Epub 2010 Aug 27.

9.

Economic benefits of using adaptive predictive models of reproductive toxicity in the context of a tiered testing program.

Martin MT, Knudsen TB, Judson RS, Kavlock RJ, Dix DJ.

Syst Biol Reprod Med. 2012 Feb;58(1):3-9. doi: 10.3109/19396368.2011.652288.

PMID:
22239076
10.

Introducing Bayesian thinking to high-throughput screening for false-negative rate estimation.

Wei X, Gao L, Zhang X, Qian H, Rowan K, Mark D, Peng Z, Huang KS.

J Biomol Screen. 2013 Oct;18(9):1121-31. doi: 10.1177/1087057113491495. Epub 2013 May 29.

PMID:
23720569
11.

Quantification of frequent-hitter behavior based on historical high-throughput screening data.

M Nissink JW, Blackburn S.

Future Med Chem. 2014 Jun;6(10):1113-26. doi: 10.4155/fmc.14.72.

PMID:
25078133
12.

Understanding false positives in reporter gene assays: in silico chemogenomics approaches to prioritize cell-based HTS data.

Crisman TJ, Parker CN, Jenkins JL, Scheiber J, Thoma M, Kang ZB, Kim R, Bender A, Nettles JH, Davies JW, Glick M.

J Chem Inf Model. 2007 Jul-Aug;47(4):1319-27. Epub 2007 Jul 4.

PMID:
17608469
13.

Experimental design and statistical methods for improved hit detection in high-throughput screening.

Malo N, Hanley JA, Carlile G, Liu J, Pelletier J, Thomas D, Nadon R.

J Biomol Screen. 2010 Sep;15(8):990-1000. doi: 10.1177/1087057110377497.

PMID:
20817887
14.

Computational models for in-vitro anti-tubercular activity of molecules based on high-throughput chemical biology screening datasets.

Periwal V, Kishtapuram S; Open Source Drug Discovery Consortium, Scaria V.

BMC Pharmacol. 2012 Mar 31;12:1. doi: 10.1186/1471-2210-12-1.

15.

High-throughput screening and small animal models, where are we?

Giacomotto J, Ségalat L.

Br J Pharmacol. 2010 May;160(2):204-16. doi: 10.1111/j.1476-5381.2010.00725.x. Review.

16.

Using economic optimization to design high-throughput screens.

Swamidass SJ.

Future Med Chem. 2013 Jan;5(1):9-11. doi: 10.4155/fmc.12.186. No abstract available.

PMID:
23256806
17.

Robust statistical methods for hit selection in RNA interference high-throughput screening experiments.

Zhang XD, Yang XC, Chung N, Gates A, Stec E, Kunapuli P, Holder DJ, Ferrer M, Espeseth AS.

Pharmacogenomics. 2006 Apr;7(3):299-309.

PMID:
16610941
18.

Projected cost-effectiveness of statewide universal newborn hearing screening.

Keren R, Helfand M, Homer C, McPhillips H, Lieu TA.

Pediatrics. 2002 Nov;110(5):855-64.

PMID:
12415021
19.

Newborn hearing screening: the great omission.

Mehl AL, Thomson V.

Pediatrics. 1998 Jan;101(1):E4.

PMID:
9417168
20.

Integration of virtual and high throughput screening in lead discovery settings.

Polgár T, Keseru GM.

Comb Chem High Throughput Screen. 2011 Dec;14(10):889-97. Review.

PMID:
21843143
Items per page

Supplemental Content

Write to the Help Desk